Get the Stockscreener App
4.08
1.69%
-0.07
After Hours:
4.08
Ars Pharmaceuticals Inc stock is traded at $4.08, with a volume of 1.03M.
It is down -1.69% in the last 24 hours and down -28.67% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
See More
Previous Close:
$4.15
Open:
$4.18
24h Volume:
1.03M
Relative Volume:
0.52
Market Cap:
$405.75M
Revenue:
$98.99M
Net Income/Loss:
$-197.98M
P/E Ratio:
-2.0383
EPS:
-2.0017
Net Cash Flow:
$-175.32M
1W Performance:
-0.73%
1M Performance:
-28.67%
6M Performance:
-48.35%
1Y Performance:
-57.23%
1-Day Range:
$4.02
$4.18
1-Week Range:
$4.02
$4.57
52-Week Range:
$4.02
$13.15
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
4.08 | 405.75M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Northland Capital | Outperform |
| Nov-04-25 | Resumed | Roth Capital | Buy |
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Class Action Filed Against ARS Pharmaceuticals, Inc. (SPRY) Over Securities ViolationsContact Levi & Korsinsky Today - accessnewswire.com
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026 - Barchart.com
Robbins LLP Reminds SPRY Stockholders of the Pending - GlobeNewswire
Securities Lawsuit Alert: ARS Pharmaceuticals, Inc. (SPRY)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with ... - Black Hills Pioneer
Shareholders of ARS Pharmaceuticals, Inc. (SPRY): Protect Your Rights Before October 5, 2026Contact Levi & Korsinsky - ACCESS Newswire
Join Class Action to Recover Losses from ARS Pharmaceuticals, Inc. (SPRY)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASD - The National Law Review
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm Before Lead Plaintiff Deadline on October 5, 2026 - Barchart.com
Did You Lose Money on ARS Pharmaceuticals, Inc. (SPRY)? Levi & Korsinsky Urges Investors to Act Before October 5, 2026 - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky for Information Before October 5, 2026ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class ActionContact SueWallSt - prnewswire.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire Inc.
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 - prnewswire.com
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights - The Globe and Mail
Class Action Lawsuit Filed: ARS Pharmaceuticals, Inc. (SPRY)Join by October 5, 2026Contact Levi & Korsinsky - ACCESS Newswire
SPRY ALERT: Securities Fraud Class Action Launched Against ARS Pharmaceuticals, Inc.October 5, 2026 Deadline - ACCESS Newswire
Contact Levi & Korsinsky by October 5, 2026 to Join Class Action Against ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Kaplan Fox Alerts Investors to an Upcoming Deadline of October 5, 2026 in the ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Securities Class Action - Barchart.com
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSPRY - TMX Newsfile
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action NoticeContact Levi & Korsinsky - prnewswire.com
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky For Information Before October 5, 2026ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Seek Leadership in a Securities Fraud Lawsuit by October 5, 2026 - NewMediaWire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY - FinancialContent
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of ARS Pharmaceuticals Inc. to Contact the Firm Today! - ACCESS Newswire
Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026 - NewMediaWire
Levi & Korsinsky Notifies ARS Pharmaceuticals, Inc. (SPRY) Shareholders of Class Action Lawsuit and October 5, 2026 Deadline - ACCESS Newswire
SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - morning-times.com
SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline - Morningstar
SPRY Shareholders Have Opportunity to Lead ARS Pharmaceuticals In - The National Law Review
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SPRY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds AR - The National Law Review
Kaplan Fox & Kilsheimer LLP Reminds Investors of a Securities Class Action Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and Lead Plaintiff Deadline on October 5, 2026 - FinancialContent
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action LawsuitInvestors Should Contact SueWallSt - prnewswire.com
ARS Pharmaceuticals Inc (SPRY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SPRY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors - GlobeNewswire
LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) SharesPurchased Between March and June 2026Should Contact the Shareholders Foundation - businesswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
SPRY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Robbins LLP Reminds Investors of the Securities Fraud Class - GlobeNewswire
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):